Marker Therapeutics Inc (MRKR)

Marker Therapeutics (MRKR) Stock Price & Analysis


MRKR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.67 - $6.60
Previous Close$1.28
Average Volume (3M)141.33K
Market Cap
Enterprise Value$12.35M
Total Cash (Recent Filing)$6.40M
Total Debt (Recent Filing)$7.49M
Price to Earnings (P/E)-0.4
Aug 10, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.96
Shares Outstanding8,798,829
10 Day Avg. Volume28,991
30 Day Avg. Volume141,328
Standard Deviation0.27
Financial Highlights & Ratios
Price to Book (P/B)1.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.63
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Marker Therapeutics Inc’s price range in the past 12 months?
Marker Therapeutics Inc lowest stock price was $0.67 and its highest was $6.60 in the past 12 months.
    What is Marker Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Marker Therapeutics Inc’s upcoming earnings report date?
    Marker Therapeutics Inc’s upcoming earnings report date is Aug 10, 2023 which is in 74 days.
      How were Marker Therapeutics Inc’s earnings last quarter?
      Marker Therapeutics Inc released its earnings results on May 11, 2023. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.8 by $0.23.
        Is Marker Therapeutics Inc overvalued?
        According to Wall Street analysts Marker Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Marker Therapeutics Inc pay dividends?
          Marker Therapeutics Inc does not currently pay dividends.
          What is Marker Therapeutics Inc’s EPS estimate?
          Marker Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Marker Therapeutics Inc have?
          Marker Therapeutics Inc has 8,798,829 shares outstanding.
            What happened to Marker Therapeutics Inc’s price movement after its last earnings report?
            Marker Therapeutics Inc reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.8. Following the earnings report the stock price went down -7.042%.
              Which hedge fund is a major shareholder of Marker Therapeutics Inc?
              Among the largest hedge funds holding Marker Therapeutics Inc’s share is Aisling Capital Management LP. It holds Marker Therapeutics Inc’s shares valued at 1M.


                Marker Therapeutics Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Marker Therapeutics Inc

                Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.


                Top 5 ETFs holding MRKR

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold MRKR. The ETFs are listed according to market value of MRKR within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                CASI Pharmaceuticals
                Spruce Biosciences
                Codiak BioSciences
                Inhibitor Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis